SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vivus, Why the Slide?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MisterED who wrote (3237)9/1/1997 12:29:00 PM
From: Cacaito   of 3991
 
Per K. who will be the subject of the takeover? Vivus, Any company taking Vivus will have to pay a very steep premium (50% to 100%) and probably few has the money for this ( $2 to $3 billions ). Vivus can take over other smaller and struggling companies, Zona could be one Vivus could be a winner here with or without FDA approval of Zona's phentolamine. Zona just raised additional $60 million dollars in secondary offering, not bad, and harder to takeover.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News